Change. This is the overarching theme in Mark Bonifacio’s recent article about observations of Chinese manufacturing today, and also applies to the mergers and acquisitions and medtech manufacturing landscape in the U.S. and beyond.
Mark recently contributed to Medical Product Outsourcing magazine, providing a reflection on 2017’s M&A activity, and what this holds for 2018.
Here’s a sneak-peak of the article:
“2017 was a year of unprecedented global change, and the impacts were certainly felt in medtech and healthcare. Some of the biggest changes occurred in the United States: Businessman/reality television star Donald Trump took office and the Republican Party controlled the White House, U.S. Senate, and House of Representatives for only the second time since 1929. The GOP promised to dismantle the Patient Protection and Affordable Care Act (a.k.a., Obamacare) and then fumbled the execution of it, a new U.S. Food and Drug Administration chief assumed control of the agency, lawmakers (led by President Trump) attacked Big Pharma, catastrophic hurricanes raked the Caribbean, and Congress passed a tax plan that will affect the medical device and other industries for years to come.
Despite so many changes and uncertainty in 2017, mergers and acquisition (M&A) activity remained robust. Throughout the year, the industry saw numerous deals involving private equity, OEMs, foreign investors, and other strategic buyers who continued to use M&A as a tactic to grow their medtech platforms and holdings.”